20 "Leukemia" clinical trials found.
-
A Phase IIa Open-label Clinical Trial to Evaluate the Safety Pharmacokinetics Pharmacodynamics and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination with Venetoclax plus Decitabine in Patients with Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Induction Therapy
The first purpose of this study is to learn if combining the study drug BP1001 with the standard-of-care drugs Venetoclax and decitabine in first line ... -
AALL1732 A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494 NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy
The purpose of the study is to determine the safety and efficacy of the investigational medicine Inotuzumab Ozogamicin for patients who have NCI high risk ... -
AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
The purpose of the study is to determine how well imatinib mesylate and combination chemotherapy work in treating patients with newly diagnosed Philadelphia chromosome positive ... -
A Phase II multicenter open-label single-arm dose escalation study of Asciminib monotherapy in 2nd and 1st Line Chronic Phase Chronic Myelogenous Leukemia (ASC2ESCALATE)
This study involves two groups of people with a type of blood cancer called chronic myeloid leukemia in its early stage. In one group, there ...
-
A First in Human Study of theMenin-KMT2A (MLL1)Inhibitor JNJ-75276617 in Participants with Acute Leukemia
The primary objectives of this study are to determine the recommended phase 2 dose(s) (RP2Ds) of JNJ-75276617, as well as the safety and tolerability ... -
A Phase 3 Trial Investigating Blinatumomab (IND#117467 NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma(B-LLy)
The purpose of the trial is to determine the safety and efficacy of the investigational medicine, blinatumomab plus standard treatment for patients who have Standard ... -
AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494 NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy
The primary aim of this study is to assess in a randomized fashion whether or not the incorporation of two cycles of inotuzumab ozogamicin (InO ... -
A PHASE 1/2 DOSE ESCALATION STUDY OF THE BCL-2 INHIBITOR ZN-d5 AND THE WEE1 INHIBITOR ZN-c3 IN SUBJECTS WITH ACUTE MYELOID LEUKEMIA ZN-d5-004C
This study is designed for patients with acute myeloid leukemia.
The study is a phase 1/2 dose escalation study of the BCL-2 Inhibitor ZN-d5 ...
-
AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
The goal of this trial is to reduce treatmentrelated morbidity and mortality without adversely impacting disease free survival (DFS) in Standard Risk (SR) patients, who ... -
AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467 NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
While outcomes in SR B-ALL have improved significantly, this population still accounts for approximately half of the overall burden of relapse among children with ALL ...